Victoria Johnson

Multiple insertions were observed in affected participants, including insertions in the MECOM and PRDM16 genes.

One patient with metastatic pancreatic cancer remains alive on maintenance chemotherapy 3 years after treatment.

Investigators found a dose-dependent increase in CAART cell persistence.

Trial sponsors Pfizer, Sarepta, Genethon, and Solid Biosciences organized a group of experts to investigate shared serious AEs.

Interim data from the phase 2 Skyline trial demonstrated a 62.5% response rate.

Further data from Mustang Bio’s phase 1/2 trial will be presented at the EHA 2022 Congress.

While the lower IV dose was generally well-tolerated, the higher dose yielded cases of serious cytokine release syndrome.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The phase 1, investigator-initiated trial continues to recruit participants with B-ALL.

AFM13 is currently also being evaluated on its own in lymphoma in a phase 2 registrational study.

The first in-human phase 1 clinical trial is being conducted in Japan.

The phase 3 registration study is evaluating AB-205's efficacy in treating damaged stem cell niches.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The same therapy by Capricor Therapeutics has demonstrated efficacy in Duchenne muscular dystrophy.

Positive interim results from a phase 3 study presented at AAD 2022 bolster recently published phase 2 data.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Allogene’s clinical hold on their AlloCAR T candidates was previously lifted in January 2022.

A2 Biotherapeutics is developing CEA- and MSLN- targeted Tmod CAR T-cell therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The company’s lead cell therapy candidate, OpRegen, has demonstrated efficacy in dry AMD.

Complete results from the phase 3 GENEr8 study were published in the New England Journal of Medicine.

A sister study of AMT-130 in Europe dosed its first patients in February.

The company recently received IND clearance for a solid tumor cell therapy.

Another MSC therapy being developed by Mesoblast demonstrated efficacy earlier in March.

Significant decreases were seen in swollen and tender joint measures.

The grant, given to Indiana University School of Medicine, will fund 3 major projects to improve different aspects of hemophilia gene therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Data presented at MDA 2022 show improvements in motor and pulmonary function and patient-reported outcomes.

The new designation follows an IND clearance and fast track review in February 2022.

WU-CART-007 is the first clinical-stage allogeneic CAR therapy for T-cell malignancies in the US.